Piper Sandler Reaffirms “Overweight” Rating for Monopar Therapeutics (NASDAQ:MNPR)

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “overweight” rating reaffirmed by investment analysts at Piper Sandler in a research report issued on Wednesday, MarketBeat Ratings reports. They currently have a $76.00 target price on the stock. Piper Sandler’s target price would suggest a potential upside of 69.87% from the company’s current price.

Separately, HC Wainwright increased their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd.

Monopar Therapeutics Stock Performance

NASDAQ:MNPR opened at $44.74 on Wednesday. Monopar Therapeutics has a one year low of $1.72 and a one year high of $54.30. The stock has a market cap of $273.00 million, a PE ratio of -22.71 and a beta of 1.18. The stock has a 50 day moving average price of $36.86 and a 200 day moving average price of $22.27.

Institutional Investors Weigh In On Monopar Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MNPR. JPMorgan Chase & Co. acquired a new stake in Monopar Therapeutics during the fourth quarter worth $45,000. Geode Capital Management LLC increased its stake in Monopar Therapeutics by 174.4% during the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock worth $849,000 after acquiring an additional 24,530 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Monopar Therapeutics during the fourth quarter worth $2,861,000. Adage Capital Partners GP L.L.C. acquired a new stake in Monopar Therapeutics during the fourth quarter worth $13,182,000. Finally, RA Capital Management L.P. purchased a new position in shares of Monopar Therapeutics during the fourth quarter worth $11,247,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.